Figure 2 .

Disease-specific and recurrence-free survival curves. Disease-specific survival curves (A, C, E, G) and recurrence-free survival curves (B, D, F, H) for all cervical cancer patients included in this study with separate lines for histopathological subtypes (A, B) and for high versus low HLA-E expression shown for the histopathological subtypes separately: cervical squamous cell carcinomas (SCC; C, D), cervical adenosquamous carcinomas (ASC; E, F), and cervical adenocarcinomas (AC; G, H). Disease-specific survival was defined as time (months) from date of primary surgery until death by cervical cancer or date of last follow-up. Recurrence-free survival was defined as time (months) from date of primary surgery until date of first recurrence or date of last follow-up in case of no recurrence. HLA-E expression scores are dichotomized by the median; HLA-E high represents a final expression score ≥6 and HLA-E low represents a final expression score <6. Survival curves are generated by the Kaplan-Meier method and P values are calculated by the Log Rank (Mantel-Cox) test.